Cocrystal Pharma (NASDAQ: COCP) Gains FDA Fast Track for Norovirus Treatment
Expert Analysis Cocrystal Pharma, Inc. (NASDAQ: COCP) securing the FDA Fast Track designation for its CDI-988 candidate marks a pivotal step in antiviral drug development. This designation underscores the promising potential of CDI-988 as a novel oral treatment and prophylaxis option for norovirus infections, a condition lacking effective therapeutic interventions to date. The Fast Track status not only accelerates the development timeline but also facilitates more frequent communication with the…
